SoftBank founder Masayoshi Son speaks in futuristic terms about his company, but the success of his late-stage VC fund is still unknown.Technologyread more
Reports of Tesla vehicles spontaneously catching fire could make customers wary of EVs just as the industry ramps up production plans.Autosread more
Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Huawei Technologies will immediately lose access to updates to the Android operating system, a source close the matter told Reuters.Technologyread more
The 2019 PGA Championship wraps up on Sunday, May 19. Here's how much money the champion will earn.Earnread more
Trump's relationships with Deutsche Bank have drawn scrutiny in Congress and elsewhere. Trump sued the bank last month to prevent it from complying with Congressional...Financeread more
Consumer IPOs from Snap to Uber have been disappointing and serve as a reminder that private investors are making all the money.Technologyread more
China's currency has been an important barometer for progress in U.S.-Chinese trade talks, and right now it's signaling things aren't going well.Market Insiderread more
The outrage has even inspired a Change.org petition called "Remake Game of Thrones Season 8 with competent writers," with over half-a-million signatories and climbing.Entertainmentread more
The move comes after star runner Alysia Montaño's May 12 op-ed in the New York Times in which she detailed her experiences with Nike.Retailread more
British drug giant GlaxoSmithKline is investing $300 million in consumer genetics company 23andMe, forging a four-year collaboration to discover medicines using human genetics as a guide.
The partnership establishes GSK as 23andMe’s exclusive collaborator for drug target discovery, the companies said Wednesday. It comes with an option to extend for a fifth year, and funding and proceeds will be split equally.
The announcement comes as GSK embarks on a new research strategy under new Chief Scientific Officer Hal Barron, a drug industry veteran. The new approach focuses on the immune system, genetics and advanced analytics and technology.
It’s not the first time a pharmaceutical company has turned to genetics to improve its drug development. Amgen acquired Iceland’s deCODE Genetics in 2012 for $415 million to benefit from its unique genetic database, while Regeneron has partnered with Geisinger Health and the UK Biobank to do the same.
23andMe is a different kind of partner. It’s a direct-to-consumer genetic testing company that charges $199 for certain health and ancestry data ($99 just for ancestry). The company has more than 5 million customers, 80 percent of whom have consented to participating in research.
It doesn’t have the traditional health records that a system like Geisinger does, but conducts surveys of its users, and says, on average, one person in its database contributes to 200 different research studies.
The company has been focused on drug development of its own, hiring Genentech veteran Richard Scheller in 2015 as chief scientific officer and head of therapeutics.
Together, the companies aim to use 23andMe’s genetic database to improve selection of drug targets, finding medicines that are more likely to work and carry a lower safety risk. The collaboration is also designed to speed identification and recruitment of patients for clinical trials.